Carcinogenesis Advance Access published online on June 17, 2004
Carcinogenesis, doi:10.1093/carcin/bgh210
© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Laboratory of Cellular Carcinogenesis and Tumor Promotion, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA
* To whom correspondence should be addressed. E-mail: delucal{at}dc37a.nci.nih.gov.
Lung cancer is the leading cause of cancer related death in developed countries. Non-small cell lung cancer (NSCLC) represents 80% of the total lung cancer cases and is comprised of adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, and large cell carcinoma (LCC) subtypes. The ability of LCC to metastasize earlier than the other forms of lung cancer suggests anti-angiogenic drugs as effective agents to combat this cancer. Thalidomide is an anti-angiogenic drug that has shown promise in multiple hematological diseases, and myeloma and other cancers. However, the molecular mechanism by which thalidomide exerts its effects is poorly understood. Therefore, we evaluated the effectiveness of thalidomide on NSCLC cell growth, and found that LCC cells were growth inhibited by 40-60%. This effect seemed specific to LCC cancer cells, since other forms of NSCLC were only mildly affected by thalidomide. At the molecular level, thalidomide increased peroxisome proliferator-activated receptor gamma (PPAR
Revised June 1, 2004
Accepted June 6, 2004
CANCER BIOLOGY
The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPAR
pathway
Abstract 
) protein dose-dependently, and peroxisome proliferator response element (PPRE) activity. Further, thalidomide treatment of LCC cells decreased nuclear factor kappa B (NF
B) activity in a dose dependent fashion, increased apoptosis, and decreased the expression of angiogenic proteins. In our mouse xenograft model of lung cancer, we found that intratumoral thalidomide caused a 64% decrease in tumor growth; moreover, tumors from the thalidomide-treated mice expressed higher PPAR, than tumors from control mice. This study shows antitumor activity of thalidomide against LCC tumors and suggests a model in which thalidomide exerts its anti-tumor effects on LCC cells through the induction of PPAR and subsequent downstream signaling. To our knowledge, this is the first study to show a link between thalidomide and PPAR.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Lee, R. Rudd, P. J. Woll, C. Ottensmeier, D. Gilligan, A. Price, S. Spiro, N. Gower, M. Jitlal, and A. Hackshaw Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., November 1, 2009; 27(31): 5248 - 5254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Lin, C.-T. Shun, M.-S. Wu, and C.-C. Chen A Novel Anticancer Effect of Thalidomide: Inhibition of Intercellular Adhesion Molecule-1-Mediated Cell Invasion and Metastasis through Suppression of Nuclear Factor-{kappa}B Clin. Cancer Res., December 1, 2006; 12(23): 7165 - 7173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Han, J. D. Ritzenthaler, H. N. Rivera, and J. Roman Peroxisome proliferator-activated receptor-{gamma} ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1 Am J Physiol Lung Cell Mol Physiol, September 1, 2005; 289(3): L419 - L428. [Abstract] [Full Text] [PDF]
|
|